Recessive SLC25A46 mutations cause a spectrum of neurodegenerative disorders with optic atrophy as a core feature. We report a patient with optic atrophy, peripheral neuropathy, ataxia, but not cerebellar atrophy, who is on the mildest end of the phenotypic spectrum. By studying seven different nontruncating mutations, we found that the stability of the SLC25A46 protein inversely correlates with the severity of the disease and the patient's variant does not markedly destabilize the protein. SLC25A46 belongs to the mitochondrial transporter family, but it is not known to have transport function. Apart from this possible function, SLC25A46 forms molecular complexes with proteins involved in mitochondrial dynamics and cristae remodeling. We demonstrate that the patient's mutation directly affects the SLC25A46 interaction with MIC60. Furthermore, we mapped all of the reported substitutions in the protein onto a 3D model and found that half of them fall outside of the signature carrier motifs associated with transport function. We thus suggest that there are two distinct molecular mechanisms in SLC25A46-associated pathogenesis, one that destabilizes the protein while the other alters the molecular interactions of the protein. These results have the potential to inform clinical prognosis of such patients and indicate a pathway to drug target development.
INTRODUCTION
Recessive SLC25A46 mutations cause a syndromic spectrum, including optic atrophy, cerebellar atrophy, and axonal neuropathy (MIM# 616505) (Abrams et al., 2015) . Specific presentations range from optic atrophy-plus disorder on the mild end of the spectrum to lethal Leigh syndrome and ponto-cerebellar hypoplasia in extreme cases (Janer et al., 2016; Wan et al., 2016; Yu-Wai-Man et al., 2016) . The wide variability of clinical presentations in SLC25A46 patients likely reflects the different degrees of partial functionality conferred by different combinations of biallelic mutations. Complete loss of the SLC25A46 protein has been described with a homozygous exon 1 deletion, and a homozygous splice-site mutation, both of which are predicted to eliminate the protein product and cause infant lethality (Nguyen et al., 2017; Wan et al., 2016) .
SLC25A46 is a distant member of the mitochondrial carrier family.
While carriers typically reside in the inner mitochondrial membrane and transport solutes, SLC25A46 localizes to the outer mitochondrial membrane and is the closest human homolog to Ugo1, a yeast protein involved in mitochondrial fusion (Abrams et al., 2015; Palmieri, 2013; Sesaki & Jensen, 2001) . In humans, dominant mutations in the canonical mitochondrial fusion genes MFN2 and OPA1 cause axonal peripheral neuropathy (Charcot-Marie-Tooth type 2A) and dominant optic atrophy, respectively (Alexander et al., 2000; Delettre, Lenaers indicating overlap between these clinical presentations (Zuchner et al., 2006) . A conditional Mfn2 knockout mouse (Chen, McCaffery, & Chan, 2007) shows early onset cerebellar degeneration and lethality similar to Slc25A46 knockout mice (Li et al., 2017; Terzenidou et al., 2017) .
While an axonal sensory polyneuropathy has been described in cattle caused by mutations in the SLC25A46 orthologue (Duchesne et al., 2017) . The optic nerve, long peripheral axons, and Purkinje cells seem to be the most affected systems in patients and animal models with mutations in SLC25A46, MFN2, or OPA1.
Although the precise function of SLC25A46 is currently unknown, it is possible that it facilitates transport across the mitochondrial membrane or functions as a molecular adaptor protein similar to Ugo1 (Hoppins, Horner, Song, McCaffery, & Nunnari, 2009; Sesaki & Jensen, 2004) . In support of the adaptor hypothesis, SLC25A46 has been shown to molecularly interact with both OPA1 and MFN2, indicating that it could play a direct role in mitochondrial fusion/fission dynamics through these interactions (Janer et al., 2016; Steffen et al., 2017) .
Additionally, SLC25A46 forms a complex with the cristae remodeling protein MIC60 also known as IMMT/Mitofilin and abnormal cristae and alterations in fusion/fission dynamics have been observed in several models (Abrams et al., 2015; Duchesne et al., 2017; Janer et al., 2016; Steffen et al., 2017; Terzenidou et al., 2017) .
We report a 6-year-old boy with bilateral optic atrophy, axonal neu- 
RESULTS

Clinical report
We report on a 6-year-old boy with a history of chronic progressive ataxia and bilateral optic atrophy ( Figure 1A) . He is the eldest of two children to healthy parents who were not known to be consanguineous; however, both maternal and paternal grandfathers originated from the same village in Turkey. Our patient has a 9-monthold sister, who is well with no developmental concerns. There is no family history of ataxia, neuromuscular, or neurometabolic disorders. There was wasting distally in the lower limbs.
Normal biochemical investigations included plasma amino acids, lysosomal enzymes, very long chain fatty acids, lactate, ammonia, and homocysteine levels. Urine metabolic screen including urine organic acids was also normal. Three brain MRIs (at 10 months, 3 years, and 5½ years of age) and a cerebral perfusion study (at 4½ years of age)
were all normal, with no deep nuclei or cerebellar abnormality identified ( Figure 1B -F).
Genetic investigations
SNP microarray revealed several long contiguous stretches of homozygosity (LCSH) comprising approximately 0.8% of the genome. Interrogation of the LCSH regions using the Genomic Oligoarray and SNP Evaluation tool (Wierenga, Jiang, Yang, Mulvihill, & Tsinoremas, 2013) identified multiple genes in association with ataxia alone, optic atrophy alone, and a single gene whose phenotype combined both ataxia and optic atrophy, SLC25A46.
Whole exome sequencing (WES) identified a homozygous missense
This is a novel variant in exon 8, not previously reported in disease or population databases (ExAC, EVS). It affects a highly conserved residue ( Figure 2B ) that is predicted to be disease-causing by in-silico tools (SIFT, PolyPhen, MutationTaster, CADD score). Parental segregation studies confirm that both parents are carriers for the SLC25A46 variant detected in the proband, which has been submitted to Clinvar (https://www.ncbi.nlm.nih.gov/clinvar/variation/559386/).
The SLC25A46 gene was first described in August 2015 and there have been nine patients reported to date with mutations in this gene (Abrams et al., 2015; Charlesworth et al., 2016; Janer et al., 2016; Nguyen et al., 2017; Wan et al., 2016) . All reported individuals have compound heterozygous or homozygous variants and all have optic atrophy and neuropathy ( Figure 2A ) (Table 1) . 
The p.R257Q variant does not destabilize the protein
Given the wide range of disease severity associated with SLC25A46 mutations, we wanted to investigate the molecular mechanism that accounts for the variability in patient prognosis. A study by Wan and colleagues demonstrates that the p.L341P variant causes lethal ponto-cerebellar hypoplasia by destabilizing the protein and suggests that steady-state levels of the protein inversely correlate with the severity of the disease (Wan et al., 2016) . We cloned and expressed our patient's p.R257Q variant along with all of the mutations that had been reported during the timing of our study, p.L138R, p.T142I, p.G249D, p.P333L, p.E335D, and p.R340C. We did not investigate p.L341P because it was not known to us at the time. We transiently cotransfected HEK293T cells with each of the SLC25A46-HA tagged mutant variants. We then prepared whole cell lysates, 48 hours after transfection, and analyzed the steady-state levels of the proteins by immunoblotting. The p.P333L and p.T142I variants were the least abundant, while p.L138R, p.E335D, and p.R340C accumulated at intermediate levels. The p.G249D and p.R257Q variants were almost as abundant as the wild-type protein ( Figure 3A ). When we quantified this across multiple immunoblots, we found that all of the patient variants were significantly reduced in comparison to wild type with the exception of p.G249D and p.R257Q, which were trending but not significantly reduced ( Figure 3B ) (Supporting Information Figure S1 counted for the maximum 5 points regardless of whether or not the patient presented with all of the above criteria, the rationale being that the lethal cases are always the most severe. A summary of these calculations can be found in (Table 2 ). When we compared this clinical severity score to the average steady-state levels of the protein, we find a definitive inverse correlation between protein stability and the severity of the syndrome R 2 = 0.86 ( Figure 3C ).
SLC25A46 localizes to the outer mitochondrial membrane (Abrams et al., 2015) . To ascertain if patient mutant variants are properly targeted to the mitochondria, the SLC25A46-HA tagged constructs were transiently transfected into Lenti-X TM 293T cells, which were visualized by immunostaining with HA and TOM20 (mitochondrial outer membrane marker) antibodies. The relative fluorescent intensity of the HA staining correlate with the abundance of the proteins found by immunoblotting (Supporting Information Figure S2 ). The p.R257Q
variant has similar signal in comparison to p.G249D and wild-type, while p.L138R shows a decrease in signal intensity, while p.T142I is barely detectable. On the contrary, p.R340C shows a relatively strong signal, however it seems to mostly be outside of the mitochondria.
Interestingly, all of the severe and moderately destabilizing variants show a similar diffuse cytoplasmic staining and discordance between HA and TOM20 localizations, while p.R257Q and p.G249D variants are comparable to wild-type suggesting that the instability of some of the variants could be partially driven by their misslocalization.
To further investigate the localization of the SLC25A46 proteins we turned to larger U2OS cells and focused primarily on wild type, p.R257Q, and p.R340C because the less stable mutant proteins were not as easily detectable by immunocytochemistry. In transiently transfected cells, we found that wild type and p.R257Q primarily colocalize with the mitochondrial TOM20 marker, while p.R340C has a more diffuse pattern that shows less correlation with the mitochondria ( Figure 3D and E) and only partial overlaps with the ER (Supporting Information Figure S3 ). Meanwhile we found no significant correlation between any variants and the autophagosome markers p62 or LC3B
(Supporting Information Figure S3 and data not shown). The p.L341P
variant has been shown to be ubiquianated by MULAN and MARCH on the outer mitochondrial membrane and degraded by P97 and the proteasome (Steffen et al., 2017) . A similar mechanism likely accounts for the instability of the intermediate and severe mutations. In conclusion, the p.R257Q substitution does not markedly reduce the steady-state levels of the SLC25A46 protein or alter its intracellular localization, as we observed for the other variants associated with the more severe clinical outcomes.
p.R257Q alters SLC25A46 protein-containing complexes
To further investigate the pathological mechanisms of the novel p.R257Q mutant protein, we generated stable HEK293T cells expressing wild-type, p.R257Q, and p.R340C variants, which show similar protein levels and colocalization observed by transient transfection ( Figure 4A and B) . We next performed cell fractionation to test whether mutant proteins misslocalize to the cytoplasm. Full length wild-type, p.R257Q and p.R340C proteins are enriched in isolated mitochondria, and no preferential accumulation of p.R340C is observed in the soluble cytoplasmic fraction ( Figure 4B ), suggesting that the diffuse nonmitochondrial signal observed by immunocytochemistry may be due to HA tag processing.
SLC25A46 is a derived outer mitochondrial membrane protein homologous to yeast Ugo1. Ugo1 has been proposed to function as a properties of MFN1 are not affected by the p.R257Q variant (Figure 4D) . However, the amount of MFN2 cosedimenting with MFN1 is reduced by p.R257Q compare to WT (fraction 5 in Figure 4D ), opening the possibility that p.R257Q variant may affect MFN1 function indirectly by altering MFN2 availability. Taken together, our data suggest that, since the p.R257Q variant is relatively stable in mitochondria (Supporting Information Figure S4 ), this mutation may directly impair SLC25A46 function by altering the molecular interactions with its mitochondrial partners. Notably, p.R257Q effect on the sedimentation profile of the SLC25A46 protein-containing complexes dramatically differ from those recently reported for the destabilizing p.L341P variant, which lead to the accumulation of SLC24A46 into the higher molecular weight complexes and loss of the lower molecular weight complexes containing MFN2 and OPA1 (Steffen et al., 2017) .
p.R257Q does not occur in the stereotypic transporter motif
SLC25A46 is a highly derived member of the SLC25A mitochondrial carrier family for which there is no solved crystal structure. (Coonrod, Karren, & Shaw, 2007; Robinson, Kunji, & Gross, 2012) .
Therefore the model is still informative for comparative purposes.
Mitochondrial carriers are around 300 amino acids in length while SLC25A46 is 418 amino acids, having an extended N-terminus. All mitochondrial carriers have three well-conserved mitochondrial carrier domains (Palmieri, 2013) , but SLC25A46 has only one conserved carrier domain at 317-402 aa (e-value = 8.02e-11), while a lesser con- Meanwhile, the other half of the reported mutations, namely p.L138R, p.T142I, p.G249D, and p.R257Q, occur in the short h1-2 and h3-4 loops far away from the putative pore, suggesting that they do not directly affect transport ( Figure 5C ). Alternatively, we propose that they may affect SLC25A46 protein molecular interactions. The ATP carrier, ANT1 (SLC25A4), binds cardiolipin by clamping h1-2 to H6
and h3-4 to H2 at similar locations to p.L138R, p.T142I, p.G249D, and p.R257Q mutations ( Figure 5B ). In ANT1, the cardiolipin interactions help to stabilize the structure of the protein as well as mediate proteinlipid-protein interactions (Nury et al., 2005) . Therefore the loss of the higher molecular weight SLC25A46-containing complex associated to the p.R257Q mutation could be dependent on the destabilization of a protein-lipid interaction on the outer mitochondrial membrane.
DISCUSSION
There is a wide spectrum of clinical features associated with SLC25A46 mutations. Optic atrophy and axonal neuropathy are clinical features shared by all patients reported thus far, however, the severity of the disease is variable and sometimes lethal (Abrams et al., 2015; Janer et al., 2016; Wan et al., 2016) . The most destabilizing or lowest abundant variants are lethal. A patient with Leigh syndrome, who died at 14 months, was homozygous for the p.T142I amino acid change, which nearly eliminates the protein (Janer et al., 2016) . Another patient, who died three months after birth, was found to have compound heterozygous mutations, one resulting in a truncation at 297 amino acids and the other p.P333L variant severely destabilizing the protein (Abrams et al., 2015) . Meanwhile, a p.L341P variant reported to be severely destabilizing was identified in a proband, who died at 4 weeks of age (Wan et al., 2016) . Many of the patient's on the severe end of the spectrum have a diagnosis consistent with ponto-cerebellar hypoplasia type 1 (PCH1) and complete loss-of-function mutations were recently identified in the original Dutch PCH1 family (van Dijk et al., 2017) .
Intermediate levels of the protein do not seem to have such a strong effect on life span, although the severity of symptoms is variable. One patient with a homozygous p.R340C substitution showed optic atrophy, peripheral neuropathy, and diffuse brain and cerebellar atrophy at 28 years of age, while the individual with the p.E335D variant showed bilateral cerebellar encephalomalacia at only 5 years of age (Abrams et al., 2015) .
The most abundant variant, p.G249D, was identified in a patient with a second mutation in trans resulting in a 94 amino acid truncation. This patient represents the mildest form of the disease with optic atrophy in the first decade of life, but development of spasticity and axonal neuropathy only in the late 40 ′ s with no cerebellar abnormalities (Abrams et al., 2015) . In our functional assays, we found that our patient's homozygous p.R257Q mutation has the most similar protein stability and mitochondrial localization to p.G249D, and that the two residues converge on the same functional domain of the protein.
Although the p.R257Q patient is still less than 10 years of age, given the current lack of cerebellar abnormalities and relative stability of the protein, we are optimistic for the patient's prognosis. A major clinical challenge for patients with rare diagnoses identified through genomic testing, such as those with recessive mutations in SLC25A46, is the shift from diagnostic uncertainty to that of prognostic uncertainty. The results of our study help to answer the question as to why there is such a wide clinical variability and provide insights for other patients with mutations in the gene. It is now clear that the severity of the SLC25A46 optic atrophy spectrum disorders is directly proportional to the levels of the protein with higher levels related to a milder clinical phenotype.
SLC25A46 has a rather elusive role in mitochondrial dynamics and has been suggested to affect either mitochondrial fission or fusion (Abrams et al., 2015; Duchesne et al., 2017; Janer et al., 2016; Steffen et al., 2017; Terzenidou et al., 2017; Wan et al., 2016) . Differences in these observations could reflect the degrees of partial functionality conferred by the SLC25A46 variants and the different cell types investigated. However, both fusion and fission processes require close apposition of the outer and inner membranes of the mitochondria and SLC25A46 is a well-established player in the interactome of proteins involved in the mitochondrial contact sites. Aside from its proposed role in mitochondrial dynamics, it could be a transporter across the outer and/or inner mitochondrial membranes (Abrams et al., 2015) .
These hypotheses are not mutually exclusive and the locations of all of the reported mutations to date support both. Since the p.R257Q and p.G249D variants do not markedly destabilize the protein, they provide greater molecular insight into the function of SLC25A46. Interestingly, these mutations occur at similar locations to the cardiolipin binding sites in ANT1 (SLC25A4). This suggests that they could facilitate lipid-protein binding rather than directly facilitate transport. ANT1
dimerization is thought to occur through these lipid interactions (Nury et al., 2005) .
SLC25A46 is the most similar mammalian Ugo1 homolog; both proteins localize to the outer mitochondrial membrane and have lost most of their carrier motifs (Abrams et al., 2015) . Ugo1 is not thought to be a transporter because molecules up to 5 kDa can passively diffuse through porin channels in the outer mitochondrial membrane (Coonrod et al., 2007) . Ugo1 is hypothesized to function as a physical adaptor protein at the outer-inner membrane contact sites through its interactions with Mgm1 (OPA1) and Fzo1 (MFN1/2) where it facilitates the final lipid-mixing step of the mitochondrial fusion mechanism (Hoppins et al., 2009; Sesaki & Jensen, 2004) . Similarly, SLC25A46 has been reported to interact with the homologs OPA1 and MFN2, indicating that it could also play a role in mitochondrial dynamics through its interactions with these proteins (Janer et al., 2016) . Additionally, both Ugo1 and SLC25A46 form a complex with the cristae remodeling homologs, Fcj1 and MIC60 (Mitofilin) (Abrams et al., 2015; Harner et al., 2011; Janer et al., 2016) .
The p.R257Q mutation disrupts SLC25A46's interaction with the MIC60-containing complex and could cause a cristae defective phenotype similar to the lack of the protein despite not affecting the overall stability of the SLC25A46 protein (Janer et al., 2016) . Additionally p.R257Q may not severely alter mitochondrial dynamics because it does not abolish the SLC25A46-MFN2 interaction, as reported for the destabilizing p.L341P mutation (Steffen et al., 2017) . However, the p.R257Q variant seems to favor the accumulation of the larger MFN2-containing complex, which could ultimately impact the balance between mitochondrial fusion and fission. Overall, our results suggest that SLC25A46 plays a direct role in mitochondrial dynamics through its molecular interactions in the SLC25A46-protein complexes independent of any potential carrier function.
There is growing evidence that other members of the SLC25A family play a role mitochondrial in dynamics. OPA1-dependent cristae remodeling is facilitated through its direct interactions with members of the SLC25A family (Patten et al., 2014) . Recently, it has been demonstrated that SLC25A38 (appoptosin) that functions as an inner membrane glycine and gamma-aminolevulinic acid transporter, also interacts with MFN1 and MFN2, and plays a role in mitochondrial dynamics independent of its carrier function (Zhang et al., 2016) .
Could other SLC25A proteins cause similar neurological features as those reported for SLC25A46? The range of clinical features; optic atrophy, ataxia, axonal neuropathy, cerebellar hypoplasia, seems to be specific to SLC25A46 dysfunction versus other carrier syndromes.
Each carrier seems to be somewhat specific for various tissues such as heart, liver, muscle, or brain (Palmieri & Monne, 2016) . It is likely that the defects observed for SLC25A46 reflect its high expression in the central nervous system (Haitina, Lindblom, Renstrom, & Fredriksson, 2006) . SLC25A40, which is also highly expressed in the central nervous system, is a candidate gene for pontocerebellar hypoplasia type III (Durmaz et al., 2009 
MATERIAL AND METHODS
Genetic analysis
DNA was extracted from peripheral blood and SNP microarray was performed using the Illumina HumanCytoSNP12 v2.1 assay following the manufacturers protocols and analyzed using Illumina Karyostudio 1.4.3.0 (Build37) analysis software. Whole exome sequencing was performed using Nextera Rapid Exome Capture Kit and HiSeq 3000/4000 SBS reagents on a HiSeq 4000, and bioinformatics analysis was undertaken using Cpipe (Sadedin et al., 2015) . Sequencing analysis occurred on the GENESIS software platform as previously described (Abrams et al., 2015; Gonzalez et al., 2015) .
Cell culture
HEK293T, Lenti-X TM 293T, and U2OS cells were grown in DMEM (Gibco) supplemented with 10% fetal bovine serum and incubated at 37 • C. Stable HEK293T cells were generated by transfecting the pIRESpuro2 plasmids using Lipofectamine 3000 (Invitrogen) according to the manufacturer's protocol. Cells were transfect a total of three times in two day increments and selected in DMEM containing 5 g/mL of puromycin. Cells were maintained in 1 g/mL puromycin-containing DMEM media.
Western blot
Hek293T cells were seeded to 75% confluence in a 6-well plate and transiently transfected using Lipofectamine 3000 (Invitrogen) according to manufacturer's protocol. Three micrograms of each SLC25A46-HA construct was mixed with 1 g GFP-pcDNA3.1 as a transfection control. Forty-eight hours later, whole lysates were scraped and extracted in RIPA (Thermo Scientific) supplemented with a protease inhibitor cocktail (Roche). After sonication and centrifugation, protein lysates were quantified by BCA (Thermo Scientific).
Fifty micrograms of sample were loaded per well using the Bolt 
Immunofluorescence
Lenti-X TM 293T, HEK 293T, and U2OS cells were seeded to 75% confluence onto glass coverslips and transfected using Lipofectamine 3000 
Sucrose gradient analysis
Mitochondria were isolated from stably transfected Hek293T cells expressing either wild-type SLC25A46-HA or the R257Q variant as previously reported (Fernandez-Vizarra et al., 2010) . Mitochondrial proteins (0.8 mg) were solubilized with 0.8% digitonin in a final volume of 0.08 mL of extraction buffer (20 mM Tris-HCl pH 7.4, 100 mM KCl, 1 mM MgSO 4 , and 0.5 mM PMSF). Clarified extracts were obtained by centrifugation at 20,000 g for 15 minutes at 4 • C, mixed with standard proteins (Hemoglobin and lactate dehydrogenase (LDH)) and applied to a 7-20% sucrose gradient prepared in extraction buffer containing 0.1% digitonin. Gradients were centrifuged in a Beckman 55Ti rotor either a 28,000 rpm for 12 hours or at 45,000 rpm for 13 hours at 4 • C.
Equal volume fractions were collected from the bottom of the gradients and assayed for haemoglobin by absorption at 409 nm and for LDH activity by measuring the rate of NADH-dependent pyruvate to lactate conversion. Proteins were concentrated by trichloroacetic acid precipitation, resolved in a 12% SDS-polyacrylamide gel and analyzed by immunoblotting.
Modeling
The SLC25A46 FASTA sequence (Q96AG3) was uploaded unto the SWISS-MODEL web browser (https://swissmodel.expasy.org) and was aligned to bovine mitochondrial ADP/ATP translocase 1 (template: signature motifs were inferred from this sequence alignment. Note that SLC25A46 has a longer N-terminus that does not align to the ATP transporter and is automatically truncated from the 3D model.
Plasmids
SLC25A46-HA was subcloned into pcDNA3.1 using Q5 polymerase, introducing a 5 ′ -NheI and 3 ′ -BamHI site. Mutation constructs were generation using Q5 R Site-Directed Mutagenesis Kit (NEB) and online tools. For stable transfections, SLC25A46-HA and mutations were subcloned into pIRESpuro2 between the NheI and BamHI sites.
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